Tabor Asset Management LP acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 36,195 shares of the company's stock, valued at approximately $506,000. Tabor Asset Management LP owned 0.25% of Inhibrx Biosciences at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of INBX. Sanofi bought a new position in Inhibrx Biosciences in the 4th quarter worth approximately $17,832,000. Walleye Capital LLC bought a new position in Inhibrx Biosciences in the 4th quarter valued at $8,932,000. Slotnik Capital LLC bought a new position in Inhibrx Biosciences in the 4th quarter valued at $5,975,000. Millennium Management LLC bought a new position in Inhibrx Biosciences in the 4th quarter valued at $3,979,000. Finally, Geode Capital Management LLC bought a new position in Inhibrx Biosciences in the 4th quarter valued at $3,930,000. 82.46% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx Biosciences in a report on Thursday, May 15th.
Get Our Latest Analysis on Inhibrx Biosciences
Inhibrx Biosciences Price Performance
NASDAQ:INBX traded down $0.24 during trading hours on Friday, hitting $23.38. The stock had a trading volume of 43,858 shares, compared to its average volume of 97,374. Inhibrx Biosciences, Inc. has a one year low of $10.80 and a one year high of $24.30. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.12 and a quick ratio of 5.12. The firm has a market capitalization of $338.54 million, a price-to-earnings ratio of 0.20 and a beta of -0.04. The company has a 50 day simple moving average of $15.19 and a two-hundred day simple moving average of $13.87.
Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($2.80) EPS for the quarter, missing analysts' consensus estimates of ($2.55) by ($0.25). Research analysts forecast that Inhibrx Biosciences, Inc. will post 104.88 earnings per share for the current fiscal year.
Inhibrx Biosciences Company Profile
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibrx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.
While Inhibrx Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
